Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies

information fournie par Boursorama •02/05/2019 à 07:30

- 5 novel oncolytic immunotherapies will be developed based on Transgene's new Invir.IO(TM) platform
- Transgene to receive $10 million upon signing and is eligible to receive further development milestone payments and royalties

Strasbourg (France), May 2, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases announces the signing of a collaborative research, option and exclusive license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. Innovative oncolytic viruses resulting from this collaboration will use Transgene's proprietary next generation viral platform Invir.IO(TM).

Under the terms of the agreement Transgene will contribute its oncolytic virus expertise, including viral design and engineering, to the collaboration as well as its novel and improved Vaccinia Virus (TK-, RR-) double-deleted backbone and will be responsible for in-vitro pre-clinical development. AstraZeneca will select the transgenes to be encoded within the virus and will be responsible for further in-vivo pre-clinical development and, subject to option exercise, clinical development and commercialization of these novel oncolytic immunotherapies.
.../...